DK3298043T3 - SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse - Google Patents
SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK3298043T3 DK3298043T3 DK16797166.2T DK16797166T DK3298043T3 DK 3298043 T3 DK3298043 T3 DK 3298043T3 DK 16797166 T DK16797166 T DK 16797166T DK 3298043 T3 DK3298043 T3 DK 3298043T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- polypeptide compositions
- sirp polypeptide
- sirp
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562163282P | 2015-05-18 | 2015-05-18 | |
US201562266450P | 2015-12-11 | 2015-12-11 | |
PCT/US2016/032921 WO2016187226A1 (en) | 2015-05-18 | 2016-05-17 | Sirp polypeptide compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3298043T3 true DK3298043T3 (da) | 2021-02-15 |
Family
ID=57320547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16797166.2T DK3298043T3 (da) | 2015-05-18 | 2016-05-17 | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
Country Status (11)
Country | Link |
---|---|
US (3) | US9845345B2 (da) |
EP (2) | EP3298043B8 (da) |
JP (2) | JP7064234B2 (da) |
CN (2) | CN107849143B (da) |
CA (1) | CA2994935A1 (da) |
DK (1) | DK3298043T3 (da) |
ES (1) | ES2857109T3 (da) |
HK (1) | HK1252870A1 (da) |
PL (1) | PL3298043T3 (da) |
PT (1) | PT3298043T (da) |
WO (1) | WO2016187226A1 (da) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10800830B2 (en) * | 2014-08-08 | 2020-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
CN107849143B (zh) | 2015-05-18 | 2021-12-10 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
AU2016331076B2 (en) | 2015-10-01 | 2020-12-03 | Nighthawk Biosciences, Inc. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
WO2018081897A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
US20230139592A1 (en) * | 2016-12-22 | 2023-05-04 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
RU2769513C2 (ru) | 2017-01-05 | 2022-04-01 | Кахр Медикал Лтд. | Слитый белок pd1-4-1bbl и способы его применения |
WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
HUE057326T2 (hu) | 2017-01-05 | 2022-04-28 | Kahr Medical Ltd | SIRP1 Alfa-41 BBL fúziós fehérje és eljárások annak alkalmazására |
CN110546160A (zh) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | 靶向嵌合蛋白及其用途 |
MA47494A (fr) * | 2017-02-17 | 2019-12-25 | Ose Immunotherapeutics | Nouvelles utilisations d'anticorps anti-sirpg |
US20190367579A1 (en) | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
MX2019010173A (es) | 2017-02-27 | 2019-11-21 | Shattuck Labs Inc | Proteínas quiméricas basadas en el csf1r. |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
CN108623689B (zh) * | 2017-03-15 | 2020-10-16 | 宜明昂科生物医药技术(上海)有限公司 | 新型重组双功能融合蛋白及其制备方法和用途 |
CA3063622A1 (en) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | Anti-sirp.alpha. antibodies |
WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
WO2019066536A1 (ko) * | 2017-09-28 | 2019-04-04 | 한국과학기술연구원 | 신규 암 치료용 조성물 |
CA3084391C (en) * | 2017-11-20 | 2023-10-10 | Taizhou Mabtech Pharmaceutical Co., Ltd | A bifunctional fusion protein targeting cd47 and pd-l1 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US11959913B2 (en) * | 2017-12-22 | 2024-04-16 | Adienne S.A. | Quantitative cellular method for determining the biological activity of an anti-CD26 ligand |
US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
EP3843772A2 (en) * | 2018-08-31 | 2021-07-07 | ALX Oncology Inc. | Decoy polypeptides |
CN109293778B (zh) * | 2018-11-01 | 2021-09-17 | 浙江蓝盾药业有限公司 | 同时抗cd70和cd47的重链抗体及其制备方法和应用 |
WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
CN113194991A (zh) | 2018-11-26 | 2021-07-30 | 四十七公司 | 针对c-kit的人源化抗体 |
MX2021010531A (es) * | 2019-03-06 | 2021-10-01 | Jiangsu Hengrui Medicine Co | Proteina de fusion bifuncional y uso farmaceutico de la misma. |
US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
EP3976658A4 (en) * | 2019-05-24 | 2023-06-07 | Forty Seven, Inc. | CO-ADMINISTRATION REGIME OF IMMUNOTHERAPEUTIC AGENTS AGAINST C-KIT AND CD47 |
US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
EP3986441A1 (en) * | 2019-06-24 | 2022-04-27 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
CA3149897A1 (en) | 2019-09-03 | 2021-03-11 | Daniel Getts | Methods and compositions for genomic integration |
US20220411500A1 (en) * | 2019-11-18 | 2022-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of fibrosis with combined blockade of il-6 and immune checkpoint |
KR20220107223A (ko) | 2019-11-27 | 2022-08-02 | 알렉소 온콜로지 인크. | 암 치료를 위한 병용 요법 |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4157315A1 (en) | 2020-06-01 | 2023-04-05 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
TW202219069A (zh) * | 2020-09-04 | 2022-05-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | SIRPγ變體及其融合蛋白 |
KR20230133837A (ko) | 2020-11-04 | 2023-09-19 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
KR20220138909A (ko) | 2021-04-06 | 2022-10-14 | 주식회사 이뮤노로지컬디자이닝랩 | Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
AU2022273727A1 (en) | 2021-05-13 | 2023-11-09 | ALX Oncology Inc. | Combination therapies for treating cancer |
US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
KR20240034954A (ko) * | 2022-09-07 | 2024-03-15 | 주식회사 시프트바이오 | SIRPα 변이체에 특이적으로 결합하는 항체 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
WO2010083253A2 (en) * | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
EP2524927A1 (en) * | 2011-05-20 | 2012-11-21 | Covagen AG | New chymase binding compounds and medical uses thereof |
US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
JP6460796B2 (ja) * | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性sirp−アルファ試薬 |
WO2014121093A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
EP3311824B1 (en) * | 2013-02-05 | 2020-03-25 | The Board of Trustees of the Leland Stanford Junior University | Cd47 targeted therapies for the treatment of infectious disease |
CN107849143B (zh) | 2015-05-18 | 2021-12-10 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
-
2016
- 2016-05-17 CN CN201680042272.5A patent/CN107849143B/zh active Active
- 2016-05-17 CA CA2994935A patent/CA2994935A1/en active Pending
- 2016-05-17 DK DK16797166.2T patent/DK3298043T3/da active
- 2016-05-17 PL PL16797166T patent/PL3298043T3/pl unknown
- 2016-05-17 PT PT167971662T patent/PT3298043T/pt unknown
- 2016-05-17 WO PCT/US2016/032921 patent/WO2016187226A1/en active Application Filing
- 2016-05-17 EP EP16797166.2A patent/EP3298043B8/en active Active
- 2016-05-17 EP EP20216691.4A patent/EP3872086A1/en active Pending
- 2016-05-17 CN CN202111592370.5A patent/CN114425077A/zh active Pending
- 2016-05-17 ES ES16797166T patent/ES2857109T3/es active Active
- 2016-05-17 JP JP2017560324A patent/JP7064234B2/ja active Active
- 2016-05-17 US US15/157,291 patent/US9845345B2/en active Active
-
2017
- 2017-11-15 US US15/814,337 patent/US10774125B2/en active Active
-
2018
- 2018-09-21 HK HK18112214.5A patent/HK1252870A1/zh unknown
-
2020
- 2020-05-04 US US16/866,425 patent/US11407801B2/en active Active
-
2021
- 2021-11-12 JP JP2021185050A patent/JP2022036957A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022036957A (ja) | 2022-03-08 |
US20180155405A1 (en) | 2018-06-07 |
EP3298043A4 (en) | 2018-12-19 |
JP2018524282A (ja) | 2018-08-30 |
CN107849143A (zh) | 2018-03-27 |
PL3298043T3 (pl) | 2021-07-19 |
US9845345B2 (en) | 2017-12-19 |
CA2994935A1 (en) | 2016-11-24 |
US11407801B2 (en) | 2022-08-09 |
US20200270324A1 (en) | 2020-08-27 |
EP3298043A1 (en) | 2018-03-28 |
ES2857109T3 (es) | 2021-09-28 |
WO2016187226A1 (en) | 2016-11-24 |
PT3298043T (pt) | 2021-03-08 |
CN114425077A (zh) | 2022-05-03 |
US10774125B2 (en) | 2020-09-15 |
CN107849143B (zh) | 2021-12-10 |
JP7064234B2 (ja) | 2022-05-10 |
EP3298043B8 (en) | 2021-04-21 |
EP3872086A1 (en) | 2021-09-01 |
US20160340397A1 (en) | 2016-11-24 |
EP3298043B1 (en) | 2020-12-30 |
HK1252870A1 (zh) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3298043T3 (da) | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
DK3240895T3 (da) | Sammensætninger og fremgangsmåder til proteinglykosylering | |
DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3390430T3 (da) | Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3282835T3 (da) | Humaniserede SIRP?-IL-15-knockin-mus og fremgangsmåder til anvendelse deraf | |
DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3389636T3 (da) | Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler | |
DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
DK3107902T3 (da) | Forbindelser og fremgangsmåder til at hæmme fascin | |
DK3072560T3 (da) | Trampolinsystemer og fremgangsmåder til fremstilling og anvendelse deraf |